Internal medicine

Clinical endpoint

Prednisolone

Tocilizumab

Disease

Arteritis

Gastroenterology

Surgery

Randomized controlled trial

Rheumatology

Rheumatoid arthritis

Vasculitis

Giant cell arteritis

Polymyalgia rheumatica

Methylprednisolone

Glucocorticoid

Medicine

The Lancet Rheumatology

The data show a slow remission-inducing and a lasting remission-maintaining effect of tocilizumab after an ultra-short pulse of glucocorticoids in patients with newly diagnosed giant cell arteritis. As a proof-of-concept study, our data do not allow us to propose clinical recommendations.

Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study